Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)

NCT00724906 is registered in ClinicalTrials.gov with Alseres Pharmaceuticals, Inc as lead sponsor.

NCT NCT00724906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00724906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)
Lead sponsor
Alseres Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2010
Completion date
July 31, 2011
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinsonian syndromes